Tibet Weixinkang Medicine Co Ltd (603676) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.009x

Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.68 Million ≈ $2.00 Million USD) by net assets (CN¥1.53 Billion ≈ $223.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tibet Weixinkang Medicine Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Tibet Weixinkang Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tibet Weixinkang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tibet Weixinkang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Liberty Gold Corp TO:LGD	-0.229x
Shanghai GuAo Electronic Technology Co Ltd SHE:300551	-0.038x
Guangxi Nanning Waterworks Co SHG:601368	0.039x
LUBAWA SA WAR:LBW	0.058x
Dexus Industria REIT AU:DXI	0.022x
Gulf Oil Lubricants India Limited NSE:GULFOILLUB	0.014x
NRJ Group PA:NRG	0.062x
Clearfield Inc NASDAQ:CLFD	-0.004x

Annual Cash Flow Conversion Efficiency for Tibet Weixinkang Medicine Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Tibet Weixinkang Medicine Co Ltd (603676) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥1.48 Billion ≈ $216.04 Million	CN¥185.53 Million ≈ $27.15 Million	0.126x	-53.30%
2024-12-31	CN¥1.39 Billion ≈ $202.73 Million	CN¥372.78 Million ≈ $54.55 Million	0.269x	+40.51%
2023-12-31	CN¥1.34 Billion ≈ $196.13 Million	CN¥256.67 Million ≈ $37.56 Million	0.191x	-5.04%
2022-12-31	CN¥1.22 Billion ≈ $178.61 Million	CN¥246.15 Million ≈ $36.02 Million	0.202x	+26.10%
2021-12-31	CN¥1.07 Billion ≈ $156.17 Million	CN¥170.69 Million ≈ $24.98 Million	0.160x	+17.61%
2020-12-31	CN¥983.21 Million ≈ $143.87 Million	CN¥133.70 Million ≈ $19.56 Million	0.136x	+18.93%
2019-12-31	CN¥930.05 Million ≈ $136.10 Million	CN¥106.34 Million ≈ $15.56 Million	0.114x	+23.41%
2018-12-31	CN¥897.64 Million ≈ $131.35 Million	CN¥83.17 Million ≈ $12.17 Million	0.093x	+25.59%
2017-12-31	CN¥858.04 Million ≈ $125.56 Million	CN¥63.30 Million ≈ $9.26 Million	0.074x	-67.34%
2016-12-31	CN¥459.42 Million ≈ $67.23 Million	CN¥103.79 Million ≈ $15.19 Million	0.226x	-20.48%
2015-12-31	CN¥402.93 Million ≈ $58.96 Million	CN¥114.47 Million ≈ $16.75 Million	0.284x	-31.35%
2014-12-31	CN¥286.28 Million ≈ $41.89 Million	CN¥118.47 Million ≈ $17.34 Million	0.414x	+15.75%
2013-12-31	CN¥247.78 Million ≈ $36.26 Million	CN¥88.59 Million ≈ $12.96 Million	0.358x	--

About Tibet Weixinkang Medicine Co Ltd

SHG:603676 China Drug Manufacturers - Specialty & Generic

Market Cap

$550.18 Million

CN¥3.76 Billion CNY

Market Cap Rank

#11878 Global

#3439 in China

Share Price

CN¥8.64

Change (1 day)

+0.47%

52-Week Range

CN¥8.60 - CN¥14.17

All Time High

CN¥24.05